Infliximab biosimilar - Amgen

Next Previous
Drug Profile

Infliximab biosimilar - Amgen

Alternative Names: ABP-710

Latest Information Update: 22 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Rheumatoid arthritis
  • Phase I Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Ulcerative colitis
  • Preclinical Inflammation; Rheumatic disorders

Most Recent Events

  • 14 Jun 2017 Updated adverse events, pharmacokinetics and immunogenicity data from a phase I trial in Healthy subjects presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 11 Nov 2016 Adverse events, pharmacokinetics and immunogenicity data from a phase I trial in Healthy subjects presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
  • 19 Oct 2016 Phase-III development planned for Rheumatoid arthritis and development is ongoing for Inflammation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top